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Brazilian patientsIncreased levels of fetal hemoglobin (HbF, α2γ2) may reduce sickle cell anemia severity due to its ability to in-
hibit HbS polymerization and also reduce themean corpuscular HbS concentration.We have investigated the in-
ﬂuence of three known major loci on the HbF trait (HBG2, rs748214; BCL11A, rs4671393; and HBS1L-MYB,
rs28384513, rs489544 and rs9399137) and HbF levels in SCA patients from the State of Pará, Northern Brazil.
Our results showed that high levels of HbF were primarily inﬂuenced by alleles of BCL11A (rs4671393) and
HMIP (rs4895441) loci, and to a lesser extent by rs748214 Gγ-globin (HBG2) gene promoter. The SNPs
rs4671393 and rs4895441 explained 10% and 9.2%, respectively, of the variation in HbF levels, while 4.1% of
trait variation was explained by rs748214. The results can be considered as in accordance with the pattern of an-
cestry displayedby the SCA patients: 39.6% European, 29.6% African and 30.8%Native American, and reinforce the
suggestion that studies of association between genetic modiﬁers and clinical and laboratory manifestations in
Brazil must be controlled by ancestry.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
The clinical manifestations of sickle cell anemia (SCA) include
marked phenotypic heterogeneity, involving genetic and environmen-
tal factors as well. Fetal hemoglobin (HbF) levels and concomitant α-
thalassemia are the two best characterized modiﬁers of severity in
SCA and β-thalassemia. α-Thalassemia modulates SCA by reducing the
intracellular concentration of sickle cell hemoglobin (HbS), which de-
creases HbS polymer-induced cellular damage and in turn ameliorates
hemolysis. High HbF levels may reduce SCA severity due to its ability
to inhibit HbS polymerization and also reduce the mean corpuscular
HbS concentration (reviewed in [1,2]). Previous genetic association
studies found single nucleotide polymorphisms (SNPs) in the Gγ-
globin (HBG2) gene promoter (chromosome 11p) in BCL11A (chromo-
some 2p) regions and in HBS1L-MYB intergenic polymorphism (HMIP;
chromosome 6q) associated with HbF levels (reviewed in [3,4]).. This is an open access article underThe effect of these SNPs onHbF levels have been investigatedmainly
in patientswith predominantly African or European ancestry. This study
aimed to validate SNPs commonly studied (HBG2, rs748214; BCL11A,
rs4671393; and HBS1L-MYB, rs28384513, rs489544 and rs9399137)
and to analyze the effect of genetic admixture on the distribution of
these SNPs in a sample of SCA patients from Belém, capital of Pará
State, Brazilian Amazon. The sickle cellmutation is absent amongNative
American populations and was introduced into the American continent
by geneﬂow fromAfrica during the Atlantic slave trade from the 16th to
the 19th century. Africansmixedwith Native Americans and Europeans
to various extents across the continent, so that SCA patients exhibit dif-
ferent levels of admixturemainly European andNative American origin,
as observed in the general population. In Brazil, although the popula-
tions of all geographic regions are the result of interbreeding between
Europeans, Africans and Native Americans, there are slight differences
in admixture proportions. European ancestry is the most prevalent in
all urban populations, but is higher in the southeast and south, while
in theNortheast,Midwest and Southeast, the African ancestry in general
is the secondmost prevalent. The Native American ancestry is higher in
the North and in general more prevalent than the African contributionthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 2
Comparison of HbF levels between genotypes.
Locus SNP/genotypes N Mean rank Mann–Whitney U P
BCL11A rs467139
GG 93 72.73 2393.000 0.001
AG + AA 74 98.16
HBS1L-MYB rs283845
AA 108 85.87 2984.500 0.500
AC + CC 59 80.58
HBS1L-MYB rs489544
AA 120 75.63 1815.000 b0.001
AC + CC 47 105.38
HBS1L-MYB rs939913
AA 130 78.15 1644.000 0.423
AG + GG 28 85.79
HBG2 rs489544
GG 120 75.63 1815.000 b0.001
AG + AA 47 105.38
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the level of mixing in SCA patients has obvious implications on the dis-
tribution of SNPs, and therefore on the levels of HbF and clinical
manifestations.
Materials and methods
Blood samples from SCA patients attended at the Center for
Hemotherapy and Hematology of Pará Foundation — HEMOPA, in
Belém, capital of Pará state, Northern Brazil, were selected for this
study. HEMOPA is the reference center for diagnosis and treatment of
hemoglobinopathies in the region. The frequency of the HBB*S gene in
this population is estimated at 0.016 and the expected number of SCA
patients in this population (384) is in accordance with the number of
patients registered at HEMOPA, approximately 400 patients, at the
time the samples were selected. Of the 240 patients initially selected
those younger than 5 years and those under treatment with hydroxy-
urea™were excluded resulting in a sample of 167 patients (47% of reg-
istered patients).
Of the 167 study subjects, 89 (53.2%) were female. The mean (SD)
age was 18.0 (10.6) years and the median age was 15.0 (IQR 10.0–
24.0) years. HbF was measured by high performance liquid chromatog-
raphy (HPLC) using equipment D10-Hemoglobin A1C Testing System
(Bio Rad ®, France). The mean HbF level of the participants was 7.6%
(SD 5.2) and the median was 6.6% (IQR 3.6–9.8%). Patients presented
39.6% European, 29.6% African, and 30.8% Native Americanmean genet-
ic ancestry proportions. SNPs (HBG2, rs748214; BCL11A, rs4671393;
HBS1L-MYB, rs28384513, rs489544 and rs9399137) were determined
by a TaqMan SNP genotyping assay (Applied BioSystems, Foster City,
CA, USA) according to the manufacturer's instruction. Pre-designed
probes were ordered for genotyping analyses. About 10–50 ng of DNA
were ampliﬁed with 5 μl of 2X TaqMan Universal PCR master mix,
0.5 μl of 40× primer and TaqMan probe dye mix. Cycling conditions
consisted of 10 min at 95 °C, followed by 40 cycles 15 s at 92 °C,
1 min at 60 °C. Allelic discrimination was performed on an Applied
BioSystem RT-PCR system.
To correct for the skewness of the HbF percentage, the values were
log10-transformed to create a nearly normally distributed quantitative
trait. The genetic association of this trait with SNP alleles was analyzed
through multiple linear regression (SPSS, Version 12, IBM) with age
and sex as covariates. TheMann–Whitney U test was used to determine
whether there were differences between the HbF level distribution ac-
cording to the presence or absence of minor allele frequency (MAF) in
the studied loci. An overall signiﬁcance level of 0.05 was set for statisti-
cal analyses.
Results and discussion
BCL11A (2p16)
Allele A of rs4671393 (BCL11A) was associated with increased HbF
levels and genotypes containing the minor allele exhibited signiﬁcantly
higher HbF levels. In addition, 10% of the trait variance among SCATable 1
SNPs at the BCL11A, HBS1L-MYB and HBG2 loci in Brazilian SCA patients.
Locus SNP Allele change MAF (allele
Chromosome 2
BCL11A rs4671393 A → G 0.243 (A)
Chromosome 6
HBS1L-MYB rs28384513 A → C 0.195 (C)
HBS1L-MYB rs4895441 A → G 0.136 (G)
HBS1L-MYB rs9399137 T → C 0.083 (C)
Chromosome 11
HBG2 rs748214 G → A 0.068 (A)
MAF, minor allele frequency.patients from Northern Brazil was explained by genetic variation at
rs4671393 alone (Tables 1 and 2). Similar results were observed in
Brazilian and African American [6], and Tanzanian and African British
SCA patients [7]. Our results are also consistent with those seen in
African American SCA patients, in whom the minor allele frequency
(MAF) was signiﬁcantly higher in patients with high HbF levels (at
least 10%) than in patients with low HbF levels [8]. Another SNP in
BCL11A gene correlatedwith HbF in SCA patients of different ethnicities
is rs11886868. However, since these SNPs are in strong linkage disequi-
librium, we have chosen to investigate only rs766432, considered to be
the one most highly correlated with HbF in SCA populations.HBS1L-MYB intergenic region (HMIP, 6q23)
HMIP polymorphisms are distributed in three disequilibrium blocks,
referred to as HBS1L-MYB intergenic polymorphism (HMIP) blocks 1, 2
and 3. Common alleles within the three haplotype blocks are associated
withHbF expression,with block 2 (24 kb) accounting for themajority of
the variance [3]. In this study, of the three genotyped SNPs (rs2838451,
block 1; rs4895441 and rs9399137, block 2), only rs4895441was signif-
icantly associated with HbF levels, explaining 9.2% of the variation in
HbF levels. Genotypes containing the minor allele of this SNP (AG and
GG) exhibited signiﬁcantly higher HbF levels when compared to geno-
type AA (Tables 1 and 2).
The association of rs28384513 and rs9399137 with HbF levels was
ﬁrst described in a sample of northern European descendants [9] and,
subsequently, the association of rs4895441 was identiﬁed in a large
nonanemic Sardinian cohort [10]. Later studies showed that these
three SNPs were associated with HbF levels in sickle cell disease (SCD)
patients from other populations: African American and Brazilian [6],
African British [7,11], and Tanzanian [7].
HMIP-2 is characterized by eleven SNPs, all of which have shown a
strong association with HbF levels in Europe, but only some of them) Effect size (SE) P Variance explained (%)
0.135 (0.033) b0.001 10.0
−0.079 (0.042) 0.062 2.3
0.222 (0.056) b0.001 9.2
0.013 (0.073) 0.861 0.0
0.152 (0.059) 0.011 4.1
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11].
The MAF of rs9399137 (C), considered themost signiﬁcantly associ-
ated with HbF expression, is less common in African populations, with
frequencies of 1–2% in African descendant SCA patients without
European admixture [7,11]. Similarly, a 3-bp (TAC) deletion, which is
in complete LD with the minor allele of rs9399137 and considered as
the functional motif for this QTL, is also more common in non-African
populations [12]. However, the minor allele of rs9399137 (C) was
foundwith signiﬁcantly higher frequencies in African American SCA pa-
tients with HbF unusually higher than among patients with low HbF
(18% versus 3%; P= 0.02) [8]. The authors suggested that somepatients
with markedly elevated HbF might have inherited the minor allele of
rs9399137 due to European genetic admixture. In summary, the
HBS1L-MYB intergenic polymorphism is also associated with HbF
among SCA patients of African ancestry, althoughmuch less signiﬁcant-
ly so when compared with European and Chinese patients because of
their much lower MAF (review in [4]).
Xmn1-HBG2
Positive association between the MAF of rs7482144 (A), in the Gγ-
globin (HBG2) gene promoter, and HbF levels, has been well document-
ed in Tanzanian patients selected from the Muhimbili Sickle Cell Collab-
orative Program [6], in Dar-es-Salaam [7], and in African American SCD
patients selected from the Cooperative Study of Sickle Cell Disease
(CSSCD) [13]. However, no signiﬁcant effects of rs7482144 on HbF levels
were found in African British patients of African-Caribbean (Jamaican,
Trinidanian) or West African (Nigerian, Ghanaian, Sierra Leonean) de-
scent, selected from King's College Hospital, in London, nor in African
Brazilian patients from the State of Pernambuco, Brazil — northeastern
region [6]. Further evidence of the inﬂuence of rs7482144 on HbF levels
has been obtained in African–American patients also selected from the
CSSCDwhen patients with high levels of HbF who showed the minor al-
lele (A) presented a frequency signiﬁcantly higher than that found
among those with low levels of HbF (30% versus 10%, P = 0.002). How-
ever, the frequencies of the A allele of rs7482144 were not different be-
tween high and low HbF groups in another sample of African–
American SCA patients selected from the Reference Laboratory Diagnosis
of hemoglobin in the BostonMedical Center (10% versus 8%, respectively,
P = 1.0) [8].
TheMAF of rs7482144 (A), also known as the Xmn I Gγ+, is found in
Senegal and Arab–Indian sickle cell haplotypes and is absent in the
Central African Republic or Bantu and Benin βS haplotypes. Thus, the
presence of the A allele is associated with the geographical origin of the
African component of the studied population. In the case of Brazil,
Bantu haplotype predominates in all regions, followed by the Benin hap-
lotype, which in turn is more common in Rio de Janeiro and Bahia,
reﬂecting the signiﬁcant presence of subjects from Central West Africa,
where the Benin haplotype predominates. The Senegal and Cameroon
haplotypes have low frequencies in almost all regions of Brazil. However,
a relatively high frequency of the Senegal haplotype (12%) has been
found in the state of Pará, northernBrazil [14], aﬁnding that corroborates
historical records of direct slave trade fromAfrica to Brazil. Therefore, the
observed positive association between rs7482144 and HbF levels in SCA
patients in this study can be considered an expected result, based on the
prevalence of the Senegal haplotype in this population. Similarly, the lack
of association observed in other Brazilian patients [6] is also consistent
with the distribution of beta-S haplotypes in the state of Pernambuco,
northeastern Brazil, where the Senegal haplotype is not found.
The estimated ancestry for SCA patients showed a high degree of
European, African and Native American admixture (39.6%, 29.6% and
30.8%, respectively), while for the general population of Belém, using a
set 46 ancestry-informative insertion deletion polymorphisms, the
mean proportions of ancestry were 53.7% European, 16.8% African and
29.5% Native American [15]. Patients showed lower Europeancontribution, but higher proportions of African andNative American an-
cestries than the general population. The pattern of ancestry displayed
by patients with sickle cell anemia certainly inﬂuenced the distribution
of SNPs studied and demonstrates that studies of association between
geneticmodiﬁers, clinical and laboratorymanifestations in Brazil should
be controlled by ancestry.
As mentioned earlier, this is a preliminary study to validate SNPs
that have been well elucidated in SCA patients with predominantly
African or European ancestry, in a sample of admixed SCA patients
from the Amazon region, resulting from the miscegenation among
European, African and Native American. If modiﬁers are associated
with genetic ancestry then the level of mixing SCA patients has obvious
implications on the distribution of SNPs, and therefore on the levels of
HbF and clinical manifestations. Thus, in Latin America populations,
where individuals tend to be more mixed than in African–American
populations, SCA patients can be considered as promising targets for ad-
mixture mapping of genetic modiﬁers of ancestry-associated SCA clini-
cal or laboratory manifestations [16,17].
More speciﬁcally regarding the African component, two aspects
must be considered: the ﬁrst refers to the proportion of contribution,
which varies from region to region, and the second refers to the origin
of the Africans brought to Brazil and the Americas. Five geographically
speciﬁc haplotypes linked to beta-S mutation are known in Africa, the
Middle East, and the Indian subcontinent, which are associated with
HbF levels. Patients with a Bantu haplotype have a lower HbF and
thosewith a Senegal or Saudi-Indian haplotype, which have the highest
HbF; individuals with a Benin haplotype have intermediate HbF levels
(reviewed in [4]). Senegal and Arab–Indian sickle cell haplotypes in-
clude rs7482144, CT polymorphism 158 bp upstream of HBG2
(rs7482144), the restriction site polymorphism Xmn1 CT that is associ-
ated with high HbF G γ-globin levels [18].
Data on the African slave trade revealed that about 70% of the slaves
imported into Brazil were from Bantu-speaking Africa (Angola, Congo
and Mozambique), about 26% from Central West Africa (Bight of Benin
and Bight of Biafra), and a small group from Atlantic West Africa (Sene-
gambia and Guinea-Bissau). The data also indicate that most of the small
number of slaves brought to Brazil directly from Atlantic West Africa
(Senegambia, Guinea-Bissau and Cape Verde), where the Senegal haplo-
type prevails, were brought to northern Brazil. Moreover, there is evi-
dence that the northeastern region of Brazil (Bahia, Pernambuco and
Maranhão) was heavily supplied with slaves from Central West Africa,
where the Benin haplotype prevails, until themiddle of the 19th century,
and that region probably became themost concentrated area of the Gold
Coast (region between the Bight of Biafra and theWindward Coast) cul-
ture in America [19,20]. Thus, this information must be the explanation
for the observed difference in the distribution of rs7482144 in patients
from Belém and those of Pernambuco [6], in the northeast, where the
contribution of people fromWest African Atlantic is lower and the pres-
ence of people from Central West Africa is higher as compared to Belém.
As an extension of this study we intend to study a large number of
other SNPs that may be associated with levels of HbF by means of
exome sequencing of SCA patients from the Amazon region controlling
for ancestry to avoid spurious association.Conclusions
Our results showed that high levels of HbF in patientswith sickle cell
anemia in the state of Para, northern Brazilwere primarily inﬂuenced by
alleles of BCL11A (rs4671393) andHMIP (rs4895441) loci, and to a less-
er extent by rs748214 Gγ-globin (HBG2) gene promoter. The SNPs
rs4671393 and rs4895441 explained 10% and 9.2%, respectively, of the
variation in HbF levels, while 4.1% of trait variation was explained by
rs748214. These results can be considered as consistent with the esti-
mates of ancestry proportions of the sample: 39.6% European, 29.6%
African and 30.8% Native American.
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